Does the time-to-onset of amiodarone-associated thyroid dysfunction differ from that of other drugs?
Monitoring for amiodarone-induced hyperthyroidism requires continuous long-term attention, whereas monitoring for hypothyroidism should focus on the early stages of treatment.
Amiodarone-associated hyperthyroidism had a different onset profile than hyperthyroidism associated with other drugs. Because the time-to-onset of AMD-associated hyperthyroidism is widely distributed, sustained and continuous attention is required to detect and treat hyperthyroidism during AMD treatment. In contrast, AMD-associated hypothyroidism had an onset profile that was similar to that of other drugs, suggesting that attention should be focused on the earlier stages of treatment.
Kinoshita et al. (Sat,) studied this question.